32539-42-7

Basic information

• Product Name: Carbamic acid, [2-(1H-indol-3-yl)ethyl]-, phenyl ester
• CAS NO: 32539-42-7
• Molecular Formula: C17H16N2O2
• Molecular Weight: 280.326
• Mol File: 32539-42-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-(1H-indol-3-yl)ethyl]-, phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(1H-indol-3-yl)ethyl]-, phenyl ester(32539-42-7)
• EPA Substance Registry System: Carbamic acid, [2-(1H-indol-3-yl)ethyl]-, phenyl ester(32539-42-7)

Safety Data

• Hazardous Substances Data: 32539-42-7(Hazardous Substances Data)

Upstream product

• 61-54-1 tryptamine 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 792909-25-2 3-(2-phenoxycarbonylamino-ethyl)-indole-1-carboxylic acid tert-butyl ester 
• 526-43-2 N²-2-methylaminobenzoyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 
• 17952-82-8 1,2,3,4-tetrahydronorharman-1-one 
• 75853-60-0 dehydroevodiamine hydrochloride 
• 1238-43-3 13b-hydroxyevodiamine 
• 1435467-23-4 C₁₇H₁₄N₂O₂ 
• 1435467-04-1 C₃₅H₃₅N₃O₆ 
• 1435467-24-5 C₁₈H₁₆N₂O₂ 
• 167015-84-1 3-(2-aminoethyl)-indole-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Investigation into the stability and reactivity of the pentacyclic alkaloid dehydroevodiamine and the benz-analog thereof

Limited synthetic approaches to obtain the biologically active alkaloid dehydroevodiamine (DHED) are known to date. Undesired demethylation in the most widely applied route was found to be a hampering side reaction for the benz-DHED derivative leading to a quinazolinone, which represents a benz-rutaecarpine derivative. For rutaecarpine, a related plant alkaloid, many different synthetic approaches have been described. Alternative reaction procedures to obtain DHED such as methylation of rutaecarpine and oxidation of evodiamine were investigated to make DHED more easily accessible and the latter method proved to be the most successful one. Furthermore, the remarkable equilibrium between the ring closed quinazolinium and the ring open form of the compounds was systematically investigated by UV-vis measurements. The ring open form and the quinazolinium salt, form the same species when incubated in buffer solution for 24 h. A better soluble form, i.e., 'hydroxyevodiamine', seems to represent the biologically active form that has not yet been described.

Optimization of rutaecarpine as ABCA1 up-regulator for treating atherosclerosis

ATP-binding cassette transporter A1 (ABCA1) is a key transporter and receptor in promoting cholesterol efflux, and increasing the expression level of ABCA1 is antiatherogenic. In our previous study, rutaecarpine (RUT) was found to protect ApoE-/- mice from developing atherosclerosis through preferentially up-regulating ABCA1 expression. In the present work, a series of RUT derivatives were synthesized and examined as ABCA1 expression up-regulators. Compounds CD1, CD6, and BCD1-2 were found to possess the most potential activity as antiatherosclerotic agents among all compounds tested.

4-AMINOMETHYL-1-ARYL-CYCLOHEXYLAMINE DERIVATIVES

The invention concerns 4-aminomethyl-1-aryl-cyclohexylamine derivatives, methods for producing same, medicines containing said compounds and the use of 4-aminomethyl-1-aryl-cyclohexylamine derivatives for producing medicines.